학술논문
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
Document Type
Article
Author
Tsai, C.J.; Shaverdian, N.; Shepherd, A.F.; Guttmann, D.; Yeh, R.; Gelblum, D.Y.; Rimner, A.; Gomez, D.R.; Lee, N.Y.; Riaz, N.; Powell, S.N.; Eng, J.; Namakydoust, A.; Preeshagul, I.; Modi, S.; Seidman, A.; Traina, T.; Drullinsky, P.; Robson, M.E.; Rudin, C.M.; Flynn, J.; Zhang, Z.; Patel, J.; Berger, M.; Reis-Filho, J.S.; Yang, J.T.; Gillespie, E.F.; Bromberg, J.; Chen, L.; Dang, C.; Das, J.P.; Eng, J.; Girshman, J.; Gucalp, A.; Hajj, C.; Higginson, D.; Iqbal, A.; Khan, A.J.; LaPlant, Q.; Mann, J.M.; Ng, K.; Reyngold, M.; Sanford, R.; Seidman, A.D.; Shah, R.; Shin, J.Y.; Sugarman, S.; Traina, T.A.; Wu, A.J.; Xu, A.J.; Zhi, W.
Source
In: The Lancet . (The Lancet, 13 January 2024, 403(10422):171-182)
Subject
Language
English
ISSN
1474547X
01406736
01406736